About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT00745875

ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study

The aim of this study is to collect initial efficacy and safety data on the use of a new treatment ZD4054 (Zibotentan) when used in combination with pemetrexed (a standard chemotherapy agent) for the ...

Lead sponsor: AstraZeneca•13 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

AstraZeneca

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Histologically or cytologically confirmed locally advanced or metastatic NSCLC on entry into study suitable for pemetrexed therapy
•Patients that meet one of the following criteria: - progressed following one prior platinum-based chemotherapy regimen for locally advanced or metastatic disease; -progressed within 6 months of adjuvant platinum-based chemotherapy
•Life expectancy of \> 12 weeks

Exclusion Criteria

•Prior treatment with pemetrexed in the last 12 months.
•Prior therapy with an ET receptor antagonist
•Any recent surgery, unhealed surgical incision, severe concomitant medical condition (eg, unstable cardiac, hepatic or renal disease) or significant laboratory finding which makes it undesirable for the patient to participate

Related studies

Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates

NCT06689488 · Lung Cancer

Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer

NCT00899405 · Lung Cancer

RECRUITINGPhase 3

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy

NCT07668037 · Non-Small Cell Carcinoma of Lung, Immunotherapy, and more

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

NCT02682667 · Multiple Myeloma, Lymphoma, Non-Hodgkin, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 6, 2012Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment66

Start dateAug 2008

Last updatedJun 6, 2012

Condition

Non Small Cell Lung Cancer Lung Cancer

Locations shown

research Site

Pleven

Research Site

Sofia

Research Site

Varna

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 6, 2012Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions